Company Directory - Wuhan Institute of Virology
Company Details - Wuhan Institute of Virology
Wuhan Institute of Virology
WebsiteWuhan, China
1 Locations
The Wuhan Institute of Virology (WIV) is known for its research on viruses and has been involved in the development and manufacture of vaccines against COVID-19, including significant work related to the Wuhan coronavirus outbreak.
CCI Score
CCI Score: Wuhan Institute of Virology
-47.75
0.03%
Latest Event
HHS Bars WIV from U.S. Funding for 10 Years
The U.S. Department of Health and Human Services announced that it has barred the Wuhan Institute of Virology from receiving federal research grants for the next 10 years due to its risky gain-of-function experiments on bat coronaviruses and its failure to respond to government inquiries.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
QUISLING
Wuhan Institute of Virology is currently rated as a Quisling.
Latest Events
- SEP202023
The U.S. Department of Health and Human Services announced that it has barred the Wuhan Institute of Virology from receiving federal research grants for the next 10 years due to its risky gain-of-function experiments on bat coronaviruses and its failure to respond to government inquiries.
-80
Business Practices and Ethical Responsibility
March 31
The Wuhan Institute of Virology conducted high-risk gain-of-function experiments and ignored multiple attempts by the government to secure accountability, which led to a severe 10‐year funding ban by HHS. This irresponsible business conduct not only jeopardizes public health but also undermines the ethical standards expected of research institutions.
HHS bars Wuhan Institute of Virology from receiving US funds for next 10 years
- JUL202023
Federal authorities suspended the Wuhan Institute of Virology’s access to US funding after the lab repeatedly failed to provide documentation on its biosafety protocols as required by NIH, raising concerns over transparency and public safety. The action, effective July 20, 2023, may lead to a longer-term ban if the lab does not address the deficiencies.
-40
Public and Political Behavior
March 31
The WIV’s repeated noncompliance with NIH biosafety documentation requirements has undermined public trust and fueled politically charged debates over COVID-19 origins, contributing to a negative impact on public and political confidence in its operation.
US halts funding access to Wuhan lab at heart of COVID-19 origins debate
-50
Business Practices and Ethical Responsibility
March 31
The lab’s failure to comply with established NIH biosafety protocols demonstrates poor business practices and a lack of ethical responsibility, compromising public safety and accountability in critical biomedical research.
US halts funding access to Wuhan lab at heart of COVID-19 origins debate
- JUL202023
On July 20, 2023, the U.S. Department of Health and Human Services (HHS) issued a memo suspending and proposing the debarment of the Wuhan Institute of Virology from participating in U.S. Federal Government procurement and nonprocurement programs. The memo cited concerns over WIV’s failure to share laboratory notebooks and electronic files related to its mouse experiments under an NIH grant, raising biosafety and transparency issues.
-40
Business Practices and Ethical Responsibility
March 31
The HHS memo highlights significant ethical concerns related to transparency and adherence to biosafety protocols. WIV’s refusal to provide laboratory records as requested by NIH implicates poor business practices and responsibility, which, under a progressive, anti-authoritarian lens, reflects an avoidance of accountability in research. This breach of ethical responsibility undermines trust in scientific practice and indirectly supports structures rooted in opaque and unaccountable operations.
- JUL192023
On July 19, 2023, the US Department of Health and Human Services terminated its funding to the Wuhan Institute of Virology following a review that identified violations of biosafety protocols and non-compliance with US regulations amid ongoing investigations into the Covid-19 lab leak theory.
-60
Business Practices and Ethical Responsibility
March 31
The termination of funding highlights serious concerns regarding the institute's failure to adhere to established biosafety protocols and comply with US regulations. This lack of ethical responsibility and operational safety in handling high-risk research contributes negatively by undermining public trust and raising questions about oversight in scientific practices related to pandemic preparedness.
- JUL182023
The Biden administration suspended federal funding for the Wuhan Institute of Virology after a monthslong review found that the institute failed to provide necessary documentation and violated NIH biosafety protocols, leading to a ban on future federal contracts.
-70
Public and Political Behavior
March 31
The institute’s failure to comply with federal safety protocols and its inability to provide required documentation demonstrates a disregard for public regulatory standards, which undermines public trust and safety. This non-compliance directly contributed to the decision to suspend federal funding, reflecting negatively on its public and political behavior.
-60
Business Practices and Ethical Responsibility
March 31
The institute’s inadequate response to federal requests and failure to adhere to established biosafety standards highlights problematic business practices and ethical responsibility. These actions compromise not only public health but also the integrity of research practices.
- JUL172023
On 17 July 2023, the US Department of Health and Human Services suspended and ended funding for the Wuhan Institute of Virology after repeated refusals to provide requested laboratory notebooks, electronic data, and other safety records. A memo sent to the House oversight subcommittee detailed these failures in communication, reflecting a significant lapse in accountability and transparency.
-50
Business Practices and Ethical Responsibility
March 31
The institute’s repeated refusal to provide critical safety and security documentation undermines accountability and transparency. This behavior, which led to the termination of federal funding, poses serious concerns about its commitment to ethical research practices and public safety, aligning with negative business practices under the ethical responsibility category.
Alternatives
New York, United States
56.72
Sunnyvale, United States
-44.83
Corporation
25.38
Corporation
0.00
Corporation
-28.01
Bethesda, United States
-11.29
Vancouver, Canada
42.04
Italy
11.68
Copenhagen, Denmark
2.36
Cambridge, United States
0.40
Industries
- 923120
- Administration of Public Health Programs
- 541712
- Research and Development in the Physical, Engineering, and Life Sciences (Biotechnology)
- 541711
- Research and Development in Biotechnology